ReviewJournal of lipid and atherosclerosis2019
The Potential Role of Biomarkers Associated with ASCVD Risk: Risk-Enhancing Biomarkers.
Review in Journal of lipid and atherosclerosis, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Association of the Triglyceride-Glucose Index with Major Adverse Cardiovascular Events in Patients with Acute Coronary Syndromes: A Systematic Review and Meta-Analysis.Medicina (Kaunas, Lithuania) · 2026Pooled it
- Comparative Safety and Efficacy of Low/Moderate-Intensity Statin plus Ezetimibe Combination Therapy vs. High-Intensity Statin Monotherapy in Patients with Atherosclerotic Cardiovascular Disease: An Updated Meta-Analysis.American journal of cardiovascular drugs : drugs, devices, and other interventions · 2024Pooled it
- Triglyceride-glucose index and the incidence of atherosclerotic cardiovascular diseases: a meta-analysis of cohort studies.Cardiovascular diabetology · 2021Pooled it
- Association of Triglyceride-Glucose Index With Different Cardiovascular Diseases in Non-Diabetic Hypertension.Journal of cellular and molecular medicine · 2025Trial
- Triglyceride-glucose index as a cardiovascular risk marker: updated evidence, limitations, and future perspectives.Lipids in health and disease · 2026Review
- Associations of Dietary Intake With Cardiovascular Diseases, Blood Pressure, and Lipid Profile in the Korean Population: An Updated Systematic Review and Meta-Analysis.Journal of lipid and atherosclerosis · 2026Article
- A 10-Year Atherosclerotic Cardiovascular Disease Risk Assessment and 5-Year Follow-Up in the Sabzevar PERSIAN Cohort Center, Northeast Iran.Iranian journal of public health · 2025Article
- Association between dynamic changes in the triglyceride-glucose index and prognosis in patients with acute ST-segment elevation myocardial infarction.Cardiovascular diabetology · 2025Article
- Derivatives of the triglyceride-glucose index and their association with incident hypertension in prehypertensive individuals: a 4-year cohort study augmented by mendelian randomization.Cardiovascular diabetology · 2025Article
- Relationship between triglyceride glucose-body mass index baselines and variation with future cardiovascular diseases risk in the middle-aged and elderly individuals.Frontiers in endocrinology · 2025Article
- Combined effect of triglyceride-glucose index and atherogenic index of plasma on cardiovascular disease: a national cohort study.Scientific reports · 2024Article
- 2024 Guidelines of the Taiwan Society of Cardiology on the Primary Prevention of Atherosclerotic Cardiovascular Disease --- Part I.Acta Cardiologica Sinica · 2024Article
- Association of triglyceride glucose index and triglyceride glucose-body mass index with sudden cardiac arrest in the general population.Cardiovascular diabetology · 2024Article
- Risk factors for atherosclerotic cardiovascular disease (ASCVD) in healthcare professionals of Azar Cohort Study: A cross-sectional Study.Health promotion perspectives · 2024Article
- Triglyceride-glucose index is associated with heart failure with preserved ejection fraction in different metabolic states in patients with coronary heart disease.Frontiers in endocrinology · 2024Article
- Opportunistic assessment of ischemic heart disease risk using abdominopelvic computed tomography and medical record data: a multimodal explainable artificial intelligence approach.Scientific reports · 2023Article
- Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris.Experimental dermatology · 2022Article
- Triglyceride-glucose index as a marker in cardiovascular diseases: landscape and limitations.Cardiovascular diabetology · 2022Review
- The Association Between Long Working Hours of Parents and Dyslipidemia in Their Children.Frontiers in public health · 2022Article
- Triglyceride-glucose index and estimated 10-year risk of a first hard cardiovascular event.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum cholesterol is major risk factor and contributor to atherosclerotic cardiovascular disease (ASCVD). Therapeutic cholesterol-lowering drugs, especially statin, revealed that reduction in low-density lipoprotein cholesterol (LDL-C) produces marked reduction of ASCVD events. In the preventive scope, lower LDL-C is generally accepted as better in proven ASCVD patients and high-risk patient groups. However, in patients with low to intermediate risk without ASCVD, risk assessment is clinically guided by traditional major risk factors. In this group, the complement approach to detailed risk assessment about traditional major risk factors is needed. These non-traditional risk factors include ankle-brachial index (ABI), high-sensitivity C-reactive protein (hsCRP) level, lipoprotein(a) (Lp[a]), apolipoprotein B (apoB), or coronary artery calcium (CAC) score. CAC measurements have an additive role in the decision to use statin therapy in non-diabetic patients 40-75 years old with intermediate risk in primary prevention. This review comprises ASCVD lipid/biomarkers other than CAC. The 2013 and 2018 American College of Cardiology/American Heart Association (ACC/AHA) guidelines suggest these factors as risk-enhancing factors to help health care providers better determine individualized risk and treatment options especially regarding abnormal biomarkers. The recent 2018 Korean guidelines for management of dyslipidemia did not include these biomarkers in clinical decision making. The current review describes the current roles of hsCRP, ABI, LP(a), and apoB in personal modulation and management of health based on the 2018 ACC/AHA guideline on the management of blood cholesterol.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.